BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 18931565)

  • 1. [Cardiac toxicity and edema].
    Takeuchi S; Sakai H
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1654-8. PubMed ID: 18931565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.
    Bengala C; Zamagni C; Pedrazzoli P; Matteucci P; Ballestrero A; Da Prada G; Martino M; Rosti G; Danova M; Bregni M; Jovic G; Guarneri V; Maur M; Conte PF;
    Br J Cancer; 2006 Apr; 94(7):1016-20. PubMed ID: 16570045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab-associated cardiotoxicity.
    Keefe DL
    Cancer; 2002 Oct; 95(7):1592-600. PubMed ID: 12237930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond chemotherapy--demystifying the new 'targeted' cancer treatments.
    Dear R; Wilcken N; Shannon J
    Aust Fam Physician; 2008; 37(1-2):45-9. PubMed ID: 18239753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiac dysfunction induced by trastuzumab].
    Campone M; Bourbouloux E; Fumoleau P
    Bull Cancer; 2004 Nov; 91 Suppl 3():166-73. PubMed ID: 15899624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac toxicity from systemic cancer therapy: a comprehensive review.
    Curigliano G; Mayer EL; Burstein HJ; Winer EP; Goldhirsch A
    Prog Cardiovasc Dis; 2010; 53(2):94-104. PubMed ID: 20728696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversing resistance to targeted therapy.
    Vidal L; Attard G; Kaye S; De Bono J
    J Chemother; 2004 Nov; 16 Suppl 4():7-12. PubMed ID: 15688600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical cardiac tolerability of trastuzumab.
    Perez EA; Rodeheffer R
    J Clin Oncol; 2004 Jan; 22(2):322-9. PubMed ID: 14722042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab beyond progression: is the risk of cardiac toxicity really not increased?
    Morabito A; Piccirillo MC; De Maio E; Di Maio M; Perrone F
    J Clin Oncol; 2009 Sep; 27(27):e123; author reply e124-5. PubMed ID: 19687322
    [No Abstract]   [Full Text] [Related]  

  • 10. Imatinib mesylate (Gleevec) induced unilateral optic disc edema.
    DeLuca C; Shenouda-Awad N; Haskes C; Wrzesinski S
    Optom Vis Sci; 2012 Oct; 89(10):e16-22. PubMed ID: 22960614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
    Gianni L; Salvatorelli E; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.
    Suter TM; Cook-Bruns N; Barton C
    Breast; 2004 Jun; 13(3):173-83. PubMed ID: 15177418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Indications for Herceptin in breast cancer treatment].
    Beuzeboc P
    Gynecol Obstet Fertil; 2004 Feb; 32(2):164-72. PubMed ID: 15123142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab versus lapatinib: the cardiac side of the story.
    Azim H; Azim HA; Escudier B
    Cancer Treat Rev; 2009 Nov; 35(7):633-8. PubMed ID: 19640652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Appearance of skin and nail toxicity in patients with breast cancer who underwent trastuzumab-containing chemotherapy].
    Adachi S; Yoshimura T; Matsuoka T; Okada K; Yasuda T; Kamei K
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1453-6. PubMed ID: 21918340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intramuscular edema as a complication of treatment with imatinib.
    Shimazaki C; Ochiai N; Uchida R; Fuchida SI; Okano A; Ashihara E; Inaba T; Fujita N; Nakagawa M
    Leukemia; 2003 Apr; 17(4):804-5. PubMed ID: 12682642
    [No Abstract]   [Full Text] [Related]  

  • 17. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
    Breccia M; Gentilini F; Cannella L; Latagliata R; Carmosino I; Frustaci A; Alimena G
    Leuk Res; 2008 Jul; 32(7):1022-5. PubMed ID: 18061664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tomorrow's targeted therapies in breast cancer patients: what is the risk for increased radiation-induced cardiac toxicity?
    Magné N; Chargari C; MacDermed D; Conforti R; Védrine L; Spano JP; Khayat D
    Crit Rev Oncol Hematol; 2010 Dec; 76(3):186-95. PubMed ID: 20138541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardiologic follow up of an oncologic patient].
    Zaugg Longchamp D; Zaman K; Aebischer N
    Rev Med Suisse; 2010 Jun; 6(251):1133-4, 1136-9. PubMed ID: 20572357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.
    Fiúza M
    Adv Ther; 2009 Jul; 26 Suppl 1():S9-17. PubMed ID: 19669637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.